Investment Rating - The report assigns an "Accumulate" rating for HashKey HLDGS (03887) with a target price of HK$7.83 [2][5]. Core Insights - HashKey is positioned as a leading compliant digital asset exchange in Asia, capitalizing on the Web3 regulatory advantages and aiming to capture significant market share in the compliant digital asset space [4][14]. - The company has a strong market presence, holding over 75% of the market share among licensed platforms in Hong Kong, and is expanding into global markets such as Bermuda and Dubai [4][6]. - HashKey's business model is evolving from a retail-driven approach to focusing on institutional clients and Omnibus partners, enhancing revenue quality and sustainability [4][5]. - Financial forecasts indicate a significant revenue increase, with projected revenues of HK$7.21 billion in 2024, HK$7.0 billion in 2025, HK$11.5 billion in 2026, and HK$20.2 billion in 2027, despite ongoing net losses [2][5][47]. - The company is expected to benefit from upcoming regulatory developments in Hong Kong, including the issuance of stablecoin licenses, which could enhance its competitive position [6][4]. Financial Summary - Revenue projections for HashKey are as follows: - 2024: HK$721 million - 2025: HK$700 million - 2026: HK$1.149 billion - 2027: HK$2.020 billion - Corresponding net profits are projected to be negative, with estimates of -HK$1.19 billion in 2024, -HK$953 million in 2025, -HK$754 million in 2026, and -HK$150 million in 2027 [2][5]. - The company is expected to optimize its cost structure, leading to a gradual reduction in losses as operational leverage improves [4][5]. Business Model - HashKey operates through three main business segments: 1. **Transaction Facilitation Services**: This includes exchange services, OTC trading, and custody services, which are expected to contribute approximately 70% of total revenue [23][27]. 2. **On-chain Services**: This segment includes staking, tokenization, and blockchain infrastructure services [23][24]. 3. **Asset Management Services**: This involves managing digital asset investment funds, including venture capital and secondary market funds [24][27]. Market Position and Strategy - HashKey is strategically positioned as a compliant digital asset exchange, leveraging its licenses and regulatory framework to attract institutional and retail clients [4][14]. - The company has a concentrated ownership structure, with key stakeholders holding 75.19% of shares, ensuring strategic alignment and stability [15][16]. - The management team comprises experienced professionals from traditional finance and technology sectors, enhancing the company's operational capabilities [19][21].

Group 1 - Crypto.com has received conditional approval from the Office of the Comptroller of the Currency (OCC) to establish Foris Dax National Trust Bank [1] - Once final approval is granted, the bank will operate as a national trust bank regulated by the OCC [1] - The bank will provide services such as digital asset custody, cross-chain staking, and transaction settlement for institutional clients [1]

Core Viewpoint - HashKey Holdings (3887.HK) officially listed on the Hong Kong Stock Exchange on December 17, 2023, becoming the first digital asset stock in Hong Kong, despite a lackluster debut performance [1][6]. Group 1: Listing Performance - On its first trading day, HashKey opened 0.3% higher, peaked at 7.12 HKD (up 6.6%), but closed at 6.67 HKD, down 0.15% with a trading volume of 666 million HKD and a turnover rate of 3.58% [1]. - The stock experienced a significant fluctuation with a daily range of 14.96% and a net outflow of 21.31 million HKD from major investors [1]. Group 2: IPO Details - HashKey's IPO was highly subscribed, with a subscription rate of 393.71 times, where 10% of shares were allocated to Hong Kong and 90% to international investors [2]. - The company issued 241 million shares at a price of 6.68 HKD per share, raising approximately 1.607 billion HKD, with a net amount of about 1.479 billion HKD after expenses [1]. Group 3: Key Investors - Notable institutional investors such as UBS Asset Management, Fidelity, and CDH Investments participated in the IPO, with a total of 9 cornerstone investors committing to a six-month lock-up period [4]. Group 4: Financial Performance - HashKey reported revenues of 129 million HKD, 208 million HKD, and 721 million HKD for the years 2022, 2023, and 2024 respectively, with cumulative losses exceeding 3.5 billion HKD [5][6]. - The company anticipates that early losses are expected as digital asset trading platforms typically require years of investment to achieve scale and profitability [6]. Group 5: Business Model and Partnerships - HashKey operates as a comprehensive digital asset financial services group, with segments including a virtual asset exchange, asset management, and Web3 infrastructure [6]. - The company has established partnerships with various banks and securities firms, focusing on trading services and the issuance of digital asset ETFs [7].

Core Insights - Galaxy Digital reported a net profit of $505 million for Q3 2025, with diluted earnings per share of $1.01 and adjusted EBITDA of $629 million, benefiting from record digital asset trading and investment gains [1] Financial Performance - The quarterly digital asset trading volume increased by 140% quarter-over-quarter [1] - The total asset platform size reached $17 billion [1] Strategic Developments - Galaxy launched the GalaxyOne platform aimed at retail investors in the U.S. in October [1] - The company announced a $460 million equity investment from a global large asset management firm [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 PUXING ENERGY LIMITED 普星能量有限公 司 普星能量有限公 司 （於開曼群島註冊成立的有限公司） （股份代號：90） 補充公告 認購HASHKEY HOLDINGS LIMITED股權 茲提述日期為二零二五年七月九日之自願性公告（「該自願性公告」），內容有 關普星能量有限公司（「本公司」，連同其附屬公司統稱「本集團」）認購HashKey Holdings Limited（「HashKey」）股權之事宜。除文義另有所指外，本公告所用詞 彙與該自願性公告所定義者具有相同涵義。董事會謹此向股東及潛在投資者 提供以下補充資料。 有關認購事項之補充資料 HashKey之持股比例： 代價基準 在同意認購事項之認購價前，董事會已委聘獨立估值機構對HashKey每單位A 系列優先股之市場價值進行評估。 該估值乃根據國際估值準則採用市場法進行。收益法被認為不適用，因其需 依賴對估值結果高度敏感之主觀 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 TIMELESS RESOURCES HOLDINGS LIMITED 天時資源控股有限公司 （於香港註冊成立的有限公司） （股份代號：8028） 自願公告 有關與HASHKEY及艾德證券戰略合作之諒解備忘錄 本公告乃由天時資源控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出以通知本公司股東及潛在投資者有關本公司最新之業務發展。 戰 略合作 諒 解備 忘錄 董 事 （「董 事 」）會 （「董事會 」）欣然宣佈， 鑒 於 與 （i ）HashKey Token Limited（ 一 間 於 新 加 坡 註 冊 成 立 之 有 限 公 司 ） （ 「 HashKey」 ） ;（ii）艾 德 證 券 期 貨 有 限 公 司 （ 一 間 於 香 港 註 冊 成 立 之 有 限 公 司 ） （ 「 艾德證 券 」 ） ;及 （iii）本 公 司 之 全 資 附 屬 公 司 白 銀 時 代 有 限 ...

Group 1 - The core point of the article is that Huajian Medical (1931.HK) has seen a significant stock price increase, rising over 12% to HKD 10.4, with a year-to-date gain exceeding 470% [1] - The company has signed a global strategic cooperation framework agreement with HashKey Group, a leading digital asset financial services group, to accelerate the implementation of its "Global Enhanced Ethereum (ETH) Treasury" strategy [1] - Ethereum's price has recently surged, surpassing USD 4600 for the first time since December 2021, which is beneficial for Huajian Medical as it has purchased 5190 ETH at an average price of USD 3661 [1]

Core Viewpoint - 华检医疗 has signed a global strategic cooperation framework agreement with HashKey Group to enhance its digital asset services and accelerate the implementation of its "Global Enhanced Ethereum (ETH) Treasury" strategy [1] Group 1: Company Developments - 华检医疗's stock price surged over 20%, reaching a new high of 9.48 HKD during trading, and is currently up 15.05% at 9.02 HKD with a trading volume of 7.94 million HKD [1] - The cooperation aims to provide more efficient, secure, and compliant digital asset services to both parties' global clients [1] Group 2: Strategic Partnership - The framework agreement will leverage HashKey Group's fully licensed compliance ecosystem to offer one-stop digital asset management services [1] - Services include large-scale trading execution and cost optimization for Ethereum (ETH), global market liquidity support, and exploring the integration of crypto asset reserves with real-world assets, particularly in medical innovation intellectual property [1] - This partnership will enable 华检医疗 to manage its Ethereum (ETH) reserves more efficiently, optimize trading costs, and access broader market resources and technical support globally [1]

Group 1 - The core strategy of the company is to launch a "Global Enhanced Ethereum Vault" with a downward protection mechanism, positioning Ethereum (ETH) as a strategic reserve asset [2][5] - The company has entered into a strategic partnership with HashKey Group, which will provide support for large-scale ETH transactions and explore the integration of crypto assets with real-world assets (RWA) [5][10] - The company has invested 149 million HKD to purchase 5,190 ETH and plans to continue increasing its holdings through a dollar-cost averaging strategy, with an approved budget of 880 million HKD [5][10] Group 2 - The "Active Coin Generation" feature is a key highlight of the company's Ethereum Vault strategy, allowing for the tokenization of innovative drug intellectual property (RWA) and trading on the ivd.xyz exchange [8][9] - The ivd.xyz exchange is the first Web3 exchange focused on medical innovation drug RWA, combining centralized and decentralized exchange features to support cross-chain trading [8][9] - The company's downward protection mechanisms include an ATM mechanism, a priority structure, RWA price buyback commitments, and a clinical VC safety net, providing comprehensive protection for investors [9] Group 3 - The Ethereum Vault strategy opens up a potential market capitalization growth space of over 100 billion HKD, drawing parallels with MicroStrategy's Bitcoin strategy, which saw an 80-fold increase in market value [10] - The company’s current market capitalization exceeds 13 billion HKD, indicating significant growth potential compared to MicroStrategy and Metaplanet [10] - The strategy aligns with the Hong Kong Monetary Authority's Ensemble project and China's innovation drug export strategy, aiming to lower financing costs and accelerate technology transfer [11]

Group 1 - The core strategy of the company is to launch a "Global Enhanced Ethereum Vault" with a downward protection mechanism, designating Ethereum (ETH) as a strategic reserve asset [2][6] - The company has entered into a strategic partnership with HashKey Group, which will provide support for large-scale ETH transactions, cost optimization, and liquidity in global markets [6][9] - The company has invested 149 million HKD to purchase 5,190 ETH and plans to continue increasing its holdings through a dollar-cost averaging strategy, with an approved budget of 880 million HKD [6][11] Group 2 - The "Active Coin Generation" feature is a key highlight of the company's Ethereum Vault strategy, allowing for the tokenization of innovative drug intellectual property (RWA) and trading on the ivd.xyz exchange [9][10] - The downward protection mechanism includes various strategies such as ATM mechanisms, priority structures, and price buyback commitments to ensure investor safety [10][11] - The company aims to replicate the success of MicroStrategy and Metaplanet by leveraging its Ethereum holdings to achieve significant market capitalization growth, with a target to exceed 100 billion HKD in two years [11][13] Group 3 - The company's Web3 exchange ecosystem and Ethereum Vault strategy create a new paradigm for financing, circulation, and revenue distribution in innovative drug development [13] - This approach aligns with the Hong Kong Monetary Authority's policy for efficient cross-border asset circulation and supports China's strategy for innovative drug commercialization [13] - The company aims to provide a compliant and transparent Web3 entry point for retail investors and patients, accelerating the availability of critical medications globally [13]